Valeant Pharmaceuticals Intl Inc (NYSE:VRX) went down -1.54% or -0.45 points to reach at $28.74 during the course of previous trade. The stock traded in the range of $28.52 – $29.59 during its most recent trading session. The stock has total market worth of $9.65B and it has total of 341.19M outstanding shares. Relative strength index (RSI-14) for Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is at 63.18.
Historically the stock has climbed 15.33% in the past week and soared 17.40% in the last four weeks, the stock illustrate that its three months performance stands at 4.62% while its year to date performance is at -71.73%. Stock’s price oscillated from $18.55 to $245.82 during past twelve months. The stock is now trading at a distance of 18.28% from SMA-20. The stock is presently trading 23.97% above from its SMA-50. In the current trading session, the stock’s price moved -47.57% below from its SMA-200. If we take a look on its volatility, 6.27 percent was seen in a week and for the month it was 5.36 percent. Stock’s beta value stands at 0.10 and its ATR value is at 1.75.
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) on August 18, 2016 announced that it has obtained the requisite lender approval for an amendment to its credit facility. The Company expects to close the amendment next week, subject to customary closing conditions. The amendment will:
- reduce the interest coverage maintenance covenant to 2.0x, providing additional headroom
- provide additional flexibility to sell assets
- permit the issuance of secured notes with shorter maturities to repay term loans
- permit the incurrence of other debt to repay term loans
The Company has also agreed to increase each of the applicable interest rate margins on its credit facility by 0.50% and to pay an amendment fee equal to 0.25% of the aggregate principal amount of each consenting lender’s outstanding loans and commitments under the credit facility.
Pfizer Inc. (NYSE:PFE) slipped -0.60% or -0.21 points in order to take the company’s stock at the price of $35.98 during previous trading session. Stock’s price oscillated between $34.83 and $35.12 for intra-day trading. Relative strength index (RSI-14) for Pfizer Inc. (NYSE:PFE) is at 44.25. It has total market capitalization of $210.91B.
Historically the stock has 0.00% in the past week and plunged -3.92% in the last four weeks, the stock illustrate that its three months performance stands at 4.54% while its year to date performance is at 11.35%. The stock hit the peak price level of one year at $37.39 and touched the minimum level of $28.25. Shares are trading -5.67% off from the 52-week high price and +27.27% above from the 52-week bottom price level. The stock is now trading at a distance of -1.94% from SMA-20. The stock is presently trading -1.06% below from its SMA-50. In the current trading session, the stock’s price moved 8.42% above from its SMA-200. The company has a Return on Assets of 4.20%. The company currently has a Return on Equity of 10.90% and a Return on Investment of 7.30%.
Pfizer Inc. (NYSE:PFE) on August 20, 2016 announced that the U.S. Food and Drug Administration (FDA) has approved TROXYCA ER (oxycodone hydrochloride and naltrexone hydrochloride) extended-release capsules, for oral use, CII for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. TROXYCA ER has properties that are expected to reduce abuse when crushed and administered by the oral and intranasal routes. However, abuse of TROXYCA ER by these routes is still possible.
TROXYCA ER extended-release capsules contain pellets that consist of oxycodone hydrochloride, an opioid agonist, which surround sequestered naltrexone hydrochloride, an opioid antagonist. When taken as directed, the naltrexone is intended to remain sequestered and patients receive oxycodone in an extended-release manner. Studies demonstrated that when the pellets are crushed the sequestered naltrexone is released and is available to counteract the effects of oxycodone.
The abuse-deterrent features of TROXYCA ER were demonstrated in a battery of in vitro laboratory studies and three clinical abuse-potential studies utilizing crushed TROXYCA ER by oral and intranasal routes of administration and the IV route (with simulated TROXYCA ER).